Clinical research studies are close to identifying potential treatments for non-transfusion-dependent Beta-thalassemia (NTDT).
I am reaching out from Leapcure to connect with you about a new phase 2a clinical trial in the following countries:
Greece (Athens, Rio, Thessaloniki), Israel (Afula, Haifa, Petah Tikva), Italy (Milan, Napoli, Orbassano, Palermo, Verona), and Thailand (Bangkok, Chiang Mai, Phitsanulok) for an investigational drug sponsored by Vifor Pharma. The investigational drug  (VIT-2763) is an oral ferroportin inhibitor which inhibits hepcidin binding to ferroportin and blocks iron efflux. 

You can learn more about the clinical trial and the investigational drug at the following links: 
https://clinicaltrials.gov/ct2/show/NCT04364269 or
https://thalassaemia.org.cy/publications/clinical-trial-updates/ferroportin-inhibitors/ 

We are searching for Beta-thalassemia patients aged 12-65 in the area who have documented diagnosis of NTDT, including a β-thalassemia intermedia-phenotype. Please let me know if you are available for a call.
Thank you,
Milcah Tesfaye
Phone : 206-605-9495
Patient Advocacy Partnerships Leader
Leapcure
Website : www.leapcure.com